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Abstract 31 
Background & Aims: Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis has been 32 
reported in irritable bowel syndrome (IBS). Enhanced HPA axis responses have been 33 
associated with reduced glucocorticoid receptor (GR) mediated negative feedback inhibition. 34 
We aimed to study the effects of IBS status, sex, or presence of early adverse life events 35 
(EAL) on the cortisol response to corticotropin-releasing factor (CRF) and adrenocorticotropic 36 
hormone (ACTH), and on GR mRNA expression in peripheral blood mononuclear cells (PBMCs). 37 
Methods: Rome III+ IBS patients and healthy controls underwent CRF (1μg/kg ovine) and ACTH 38 
(250μg) stimulation tests with serial plasma ACTH and cortisol levels measured (n=116). GR 39 
mRNA levels were measured using quantitative PCR (n=143). Area under the curve (AUC) and 40 
linear mixed effects models were used to compare ACTH and cortisol response measured 41 
across time between groups. 42 
Results: There were divergent effects of IBS on the cortisol response to ACTH by sex. In men, 43 
IBS was associated with an increased AUC (p= 0.009), but in women AUC was blunted in IBS 44 
(p=0.006). Men also had reduced GR mRNA expression (p=0.007). Cumulative exposure to EALs 45 
was associated with an increased HPA response. Lower GR mRNA was associated with 46 
increased pituitary HPA response and increased severity of overall symptoms and abdominal 47 
pain in IBS. 48 
Conclusion: This study highlights the importance of considering sex in studies of IBS and the 49 
stress response in general. Our findings also provide support for PBMC GR mRNA expression as 50 
a peripheral marker of central HPA response. 51 
52 
Keywords: Irritable bowel syndrome; Hypothalamic Pituitary-Regulating Hormones; 53 
Adrenal Cortex Hormones; Glucocorticoids Receptors; Sex Differences54 
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1. Introduction55 
Irritable bowel syndrome (IBS) is a stress-sensitive disorder. Perceived current stress is 56 
associated with first symptom onset and exacerbation in the majority of patients,(Whitehead 57 
et al., 1992) stress is a risk factor for the development of post-infectious IBS,(Gwee et al., 58 
1999) and IBS patients report a higher prevalence of early adverse life events (EALs).(Bradford 59 
et al., 2012) The response to a stressor is in part mediated by the hypothalamic-pituitary-60 
adrenal (HPA) axis. Activation of the HPA axis results in release of CRF from the 61 
paraventricular nucleus of the hypothalamus, stimulating release of adrenocorticotropic 62 
hormone (ACTH) from the anterior pituitary. ACTH stimulates the adrenal cortex to release 63 
cortisol. Cortisol attenuates the HPA axis response via negative feedback, primarily via 64 
glucocorticoid receptors (GRs), in the hypothalamus and the pituitary. 65 
1.1 HPA axis augmentation in IBS – Current evidence in humans in inconclusive 66 
In animal models, augmentation of the HPA axis has been linked to increased visceral 67 
sensitivity,(Myers and Greenwood-Van Meerveld, 2010) a cardinal feature of IBS. HPA axis 68 
studies in IBS have yielded inconsistent results (summarized with references in Appendix C). 69 
Most studies supporting augmentation of the HPA axis in IBS have measured the response to a 70 
psychological stressor. The HPA response to visceral stressors such as rectal distension or 71 
flexible sigmoidoscopy has been similar between IBS patients and HCs in most studies. 72 
Hormone challenge allows an isolated assessment of the HPA axis. To date, three studies have 73 
assessed the response to CRF in IBS vs. HCs, with two showing an increased and one showing a 74 
blunted HPA response in IBS vs. HCs.(McGowan et al., 2009a) In the largest of these studies, 75 
the patient group included only 10 with IBS alone, with 15 having IBS and non-ulcer dyspepsia 76 
and 5 with non-ulcer dyspepsia.  In a well-characterized and sufficiently large sample 77 
without psychiatric comorbidity, we aim to test the hypothesis that the HPA response at 78 
both the pituitary and adrenal level is augmented in IBS vs. HCs by comparing the area 79 
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under the curve (AUC) of the ACTH and cortisol responses to hormone stimulation, as well 80 
as the rate of rise from baseline to peak as a secondary measure. 81 
1.2 HPA axis dysregulation may be different in men and women 82 
Like other stress-related disorders, IBS is more prevalent among women. There are sex 83 
differences in the HPA response among healthy individuals, and dysregulation of the HPA axis 84 
in psychiatric disease differs by sex (e.g. lower cortisol in post traumatic stress disorder is not 85 
seen in men and in depression, cortisol is elevated to a higher degree in women).(Bohmelt et 86 
al., 2005; Dinan et al., 2006; Fukudo et al., 1998) Sex differences in the autonomic system 87 
have been described in IBS, with increased sympathetic tone and decreased vagal tone in men 88 
vs. women with IBS,(Bangasser and Valentino, 2014), but sex differences in the HPA axis in IBS 89 
have not been systematically evaluated. We planned to compare the HPA response to 90 
hormone challenge separately in men and women to test the hypotheses that a) among 91 
HCs, HPA response will be increased in women vs. men, and b) among IBS patients, HPA 92 
response will be increased in men vs. women. 93 
1.3 Peripheral glucocorticoid receptor expression 94 
The response of the HPA axis is attenuated via negative feedback though binding of 95 
cortisol to glucocorticoid receptors in the hypothalamus and pituitary, and one mechanism of 96 
HPA axis dysregulation is impairment of negative feedback by changes in GR expression, 97 
signaling or trafficking. There is evidence for a role of altered central GR signaling in IBS from 98 
preclinical studies. For example, central knockdown of GRs resulted in increased visceromotor 99 
response to colorectal distension.(Chang and Heitkemper, 2002) In humans, decreased central 100 
expression of GRs has been associated with depression in findings from autopsy 101 
specimens,(Johnson and Greenwood-Van Meerveld, 2015) and impaired negative feedback in 102 
depression is also supported by the consistent response to dexamethasone suppression or 103 
dexamethasone-CRF testing. Though negative feedback is mediated by GRs in the central 104 
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nervous system, changes in peripheral blood mononuclear cell (PBMC) GR number,(Webster et 105 
al., 2002) sensitivity,(de Kloet et al., 2007) promoter methylation status,(Yehuda et al., 106 
2004) and mRNA expression(Yehuda et al., 2015) have been reported in psychiatric disease 107 
associated with negative feedback of the HPA axis. While studies in IBS have not supported 108 
impaired negative feedback based on dexamethasone suppression, (Gola et al., 2014; Hepgul 109 
et al., 2013) PBMC GR mRNA expression has not been studied. We aimed to test the 110 
hypothesis that PBMC GR mRNA is decreased in IBS vs. HCs which could support altered 111 
negative feedback as a mechanism for IBS-associated augmentation of the HPA axis. We 112 
also aimed to test the hypothesis that PBMC GR mRNA expression is a peripheral biomarker 113 
reflecting the “activity” of the HPA axis by determining whether GR mRNA expression is 114 
correlated with basal or stimulated hormone levels. 115 
1.4 Early adverse life events 116 
Exposure to EALs is associated with GR expression, HPA response, and IBS.(Bohmelt et 117 
al., 2005; Dinan et al., 2006) We aimed to test the hypothesis that both IBS patients and 118 
HCs with EALs will have increased HPA response and decreased GR mRNA. 119 
To our knowledge, this is the largest study to evaluate the independent and 120 
interaction effects of sex, IBS status and history of EALs on the HPA axis. It is also the largest 121 
study evaluating the response to CRF in IBS, and the first study to evaluate: 1) the response to 122 
ACTH in IBS; 2) PBMC GR mRNA expression in IBS; and 3) GR mRNA together with HPA axis 123 
response to both CRF and ACTH within the same sample of participants. 124 
Videlock 
6 
2. Methods125 
All references in the methods section are in Appendix A.1 (Supplementary Material). 126 
2.1 Study Participants 127 
Rome III+ IBS patients and HCs ages 18-55 were recruited primarily by community 128 
advertisement. Bowel habit subtypes (IBS with diarrhea (IBS-D), constipation (IBS-C) and 129 
mixed pattern (IBS-M)) were based on the Rome III criteria.(A.1.a) The diagnosis was 130 
confirmed by a clinician with expertise in IBS. HCs had no personal or family history of IBS or 131 
other chronic pain conditions. Additional exclusion criteria for all subjects included: 132 
infectious or inflammatory disorders, active psychiatric illness over the past 6 months as 133 
assessed by structured clinical interview for the DSM-IV (MINI),(A.1.b) use of corticosteroids in 134 
the past six months, use of narcotics, antidepressants or other medications that could affect 135 
neuroendocrine function in the past two months, or current tobacco or alcohol abuse. 136 
Participants were compensated. Our goal was to evaluate women during the follicular phase 137 
or days 4-14 of their menstrual cycle if on oral contraceptive pills. Phase was determined by 138 
date of last menstrual period and progesterone levels. The study was approved by the UCLA 139 
Institutional Review Board, and all subjects signed a written informed consent prior to start 140 
of study. 141 
2.2 Symptom Measures 142 
IBS symptom severity over the prior week was assessed with a numeric rating scale (0-143 
20).(A.1.c) Current anxiety and depression symptoms were measured with the Hospital 144 
Anxiety and Depression (HAD) scale.(A.1.d) The presence of EALs before age 18 was 145 
determined using the Trauma History Questionnaire.(A.1.e) In addition, the Early Trauma 146 
Inventory Self Report Short Form (ETI-SR) determined the number of EAL events 147 
experienced.(A.1.f) The symptom measures for correlation with hormone response and GR 148 
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mRNA expression were obtained on the days of the screening visit. 149 
2.3 Hormone Challenge 150 
CRF stimulation test: An intravenous (IV) catheter was placed at 1:30pm. Blood 151 
samples for ACTH and cortisol levels were collected from 3:00 pm (-60 minutes) to 4:00pm (0 152 
minutes) in 30-minute intervals. At 4:00pm, 1μg/kg ovine CRF (Acthrel, Ferring, New York) 153 
was given IV. Blood samples were collected at 5, 15, 30, 60, 90, and 120 minutes after the 154 
administration of CRF.1 Participants were fasting from 10:00 am and were instructed to eat a 155 
low glycemic index breakfast. Waking times of participants were not assessed. 156 
ACTH stimulation test: The ACTH stimulation test was performed at least one week 157 
after the CRF stimulation test. IV catheters were placed into a forearm vein at 8:00 am. Blood 158 
samples for baseline ACTH and cortisol were collected at 8:30 and 9:00am. 250 μg Cortrosyn 159 
(Organon, West Orange, N.J.) was administered IV at 9:00 am. Blood samples for cortisol were 160 
collected at 30, 60, 90, 120, 150, and 180 minutes after ACTH was given. Samples were be 161 
assayed in the UCLA Neuroendocrine Assay Core. Participants were fasting. 162 
Samples were collected, processed and assays were performed according to standard 163 
operating procedures of the UCLA Clinical and Translational Research Center. The assays for 164 
ACTH and cortisol were performed with the IMMULITE system (Siemens Healthcare Diagnostics 165 
Inc). 166 
Baseline values were calculated from the average of values prior to CRF/ACTH 167 
administration. Area under the curve with respect to minimum value (AUCi) was calculated 168 
with the trapezoidal method. We also calculated rise and decline slope from the slope of the 169 
regression line from baseline to peak, and peak to lowest value after the peak, 170 
respectively.(A.1.g) 171 
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2.4 Glucocorticoid Receptor mRNA 172 
PBMCs were isolated from blood collected on a date prior to the hormone challenge 173 
assays. This was part of a separate research protocol but the inclusion and exclusion criteria 174 
were the same. Participants were not required to fast. Quantitative PCR (qPCR) determined 175 
the expression levels of GRα (active isoform) and GRβ (inactive isoform). Details of RNA 176 
extraction and qPCR are in Appendix A.3 (Supplementary Material). 177 
2.5 Statistical Analysis 178 
2.5.1 Sample size 179 
For our sample size calculation, we used an estimated mean difference in AUCi of 570 180 
(ng/L)xh based on the data from the study by Dinan et. al. and a standard deviation of 500 181 
based on values for healthy controls in the literature. Using the pwr package for R, we would 182 
have an 80% power to dectect this difference with an alpha of 0.05 with a sample size of 13 183 
per group.  184 
2.5.2 Statistical Analysis 185 
For each outcome of the three hormone challenge experiments (CRF-stimulated ACTH, 186 
CRF-stimulated cortisol, ACTH-stimulated cortisol), we calculated average baseline values, 187 
AUCi, rise slope, and decline slope (absolute value) for each subject. We compared each 188 
outcome with IBS, sex, and EAL, and tested an IBS*sex interaction using linear regression, 189 
controlling for age and body mass index (BMI).  For AUCi rise and decline we additionally 190 
controlled for baseline hormone levels. A similar analysis strategy was used for the GR mRNA 191 
outcome. If needed, outcomes were transformed to achieve approximate normality using 192 
natural logarithm or square root (Appendix A.4). Due to the presence of different hormone 193 
responses in men and women, we performed post-hoc pairwise comparisons in the linear 194 
regression models even in cases where the IBS*sex interaction was not statistically significant. 195 
For the post-hoc comparisons (IBS-Men vs. IBS-Women, Control-Men vs. Control-Women, Male-196 
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IBS vs. Male-Control, Female-IBS vs. Female-Control), we used a Bonferroni-adjusted 197 
significance threshold of p=0.0125.  198 
We also evaluated the change of hormone levels over time by group: IBS vs. controls 199 
(IBS*time), men vs. women (sex*time), or +EAL vs. –EAL (EAL*time) by piecewise mixed 200 
models with a knot at the group maximum (CRF-stimulated ACTH at 90 min, CRF-stimulated 201 
cortisol at 60 min, ACTH-stimulated cortisol at 30 min). We also evaluated the effect of the 202 
three-way interaction IBS*sex*time which assesses the statistical significance of the 203 
difference of differences (i.e. whether the difference in response over time between IBS men 204 
and HC men is significantly different from the difference between IBS women and HC 205 
women). P-values were from a likelihood ratio test evaluating the model with and without the 206 
group*time interaction term, with <0.05 considered significant.  207 
The associations of measures of hormone response with anxiety and depression 208 
symptoms and IBS overall symptom and abdominal pain severity were tested with linear 209 
regression. Correlation of GR mRNA with AUCi and baseline for each hormone challenge 210 
experiment was determined with partial correlations controlling for time interval (days) 211 
between the tests. The effect of EAL was also evaluated by the effect of Total ETI-SR score 212 
on measures of hormone response (AUCi, rise slope, decline slope) and on GR mRNA with 213 
linear regression models. 214 
As a post-hoc comparison, we evaluated bowel habit subtype groups: HCs vs IBS with 215 
constipation (IBS-C), diarrhea (IBS-D), and mixed (IBS-M).   216 
3. Results 217 
3.1 Participant characteristics 218 
All partipants in the sample were recruited as described in 2.1 and completed 219 
measures described in 2.2. This manuscript reports results from three subsets of the sample 220 
(see diagram in Appendix B.1). Results of the hormone challenge are reported for the subset 221 
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that completed this experiment (Table 1). Comparison of GR mRNA includes the subset for 222 
which GR mRNA was measured (Table 1). Finally, comparison of HPA measures with GR mRNA 223 
levels includes only participants who completed both experiments (Appendix B.3). 224 
Table 1: Participant Characteristics 225 
Variable: Mean (SD) Hormone Challengea GR mRNA 
 HC (n=56) IBS (n=60) HC (n=69) IBS (n=74) 
Female 29 (52%) 39 (65%) 36 (52%) 48 (65%) 
Age (years) 30.9 (10.9) 33.4 (11.8) 33.4 (11.8) 32.7 (11.7) 
BMI 26.9 (5.3) 25.8 (5.9) 25.7 (4.6) 26.2 (5.7) 
Ethnicity     
Hispanic 14 (25.5%) 12 (21.1%) 18 (26.5%) 14 (19.7%) 
Race 
Asian 9 (17.0%) 13 (23.2%) 16 (24.2%) 13 (18.1) 
Black/African American 13 (24.5%) 10 (17.9%) 10 (15.2%) 8 (11.1%) 
White 21 (39.6%) 24 (42.9%) 25 (37.9%) 34 (47.2%) 
Other/Mixed 10 (18.9%) 9 (16.1%) 15 (22.7%) 17 (23.2%) 
Bowel Habit Subtype     
IBS-C  16 (26.7%)  28 (38%) 
IBS-D  19 (16.4%)  26 (35%) 
IBS-M  23 (38.3)  20 (27%) 
IBS-U  2 (3.3%)  - 
Presence of EALs (<age 18) 27 (48.2%) 34 (59.7%)* 34 (54%) 37 (56%) 
HAD Anxiety score (0-21) 3.7 (2.9) 5.4 (4.2)*  3.7 (3.1) 6.4 (5.3)* 
HAD Depression score (0-21) 1.3 (1.7) 2.4 (2.9) 1.2 (1.2) 2.9 (3.5)* 
Overall IBS Severity (0-20)  10.7 (4.2)  10.0 (4.7) 
Abdominal Pain (0-20)  10.1 (4.4)  9.5 (4.4) 
asee Appendix B.1 (Supplementary Materials) for N with complete data for each analysis *p<0.05 between IBS and 226 
HCs; SD, standard deviation; HC, healthy control; IBS, irritable bowel syndrome; GR, glucocorticoid receptor; BMI, 227 
body mass index; HAD, Hospital Anxiety and Depression; EAL, early adverse life events; IBS-C, IBS with 228 
constipation; IBS-D, IBS with diarrhea; IBS-M, mixed IBS; IBS-U, unsubtyped IBS 229 
Hormone challenge participants (Table 1) were 56 HCs and 60 IBS patients (52% and 230 
65% women). Of these 116 subjects, 102 and 109 completed the CRF and ACTH stimulation 231 
tests. The number of participants by IBS and sex is shown for each experiment is shown in 232 
Appendix B.1 (Supplementary Material).  Among women, 67% and 39% (CRF and ACTH 233 
stimulation, respectively) were evaluated during the follicular phase of the menstrual cycle or 234 
days 4-14 if on oral contraceptive pills. Menstrual cycle details are shown in Appendix B.2 235 
(Supplementary Material). There was no effect of menstrual cycle on HPA response among 236 
women. GR mRNA participants (Table 1) were 69 HCs and 74 IBS patients (52% and 65% 237 
women). Participants in the GR mRNA/hormone challenge overlap group (GR mRNA within 90 238 
days of the hormone challenge) were 24 IBS patients and 23 HCs (79% and 61% women). Mean 239 
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(SD) time interval between hormone challenge and mRNA was 27.0(31.8) days and was similar 240 
in IBS and HCs (p=0.62). Clinical characteristics were similar to those of both the hormone 241 
challenge and the GR mRNA groups and are shown in Appendix B.3 (Supplementary Material).  242 
3.2 HPA axis in IBS vs HCs  243 
There were no significant IBS vs. HC differences in baseline, AUCi, rise slope or decline 244 
slope for any of the hormone tests. Using mixed models, there was an effect of IBS*time on 245 
the CRF-stimulated ACTH response (p=0.049), characterized by a slower decline following 246 
peak in IBS, but this became non-significant when controlling for sex. There were no 247 
significant effects of IBS*time on CRF- or ACTH-stimulated cortisol response (p=0.33, p=0.37). 248 
HPA axis measures did not correlate with symptoms or pain severity in IBS. 249 
3.3 HPA axis in Men vs Women 250 
There was an overall effect of sex on baseline ACTH (men > women, p<0.001) but no 251 
difference in AUCi for CRF-stimulated ACTH. Using mixed models, there was a significant 252 
effect of sex*time on CRF-stimulated ACTH response (p<0.001, likely due to a larger rise from 253 
baseline to peak among women), and CRF-stimulated cortisol (p<0.001, likely due to a slower 254 
decline from peak in women). For ACTH-stimulated cortisol, there was a significant effect of 255 
sex on decline slope with a faster decline in women vs. men (p=0.012). This was mainly 256 
accounted for by a difference within HCs (p=0.002). There was a non-significant sex*time 257 
effect on ACTH-stimulated cortisol (p=0.06). Among HCs, AUCi was greater in women than 258 
men (p=0.005) but the opposite was true in IBS (see below). 259 
3.4 HPA axis: IBS*sex 260 
For CRF-stimulated ACTH (Figure 1) and CRF-stimulated cortisol (Figure 2) there were 261 
no significant IBS*sex interaction effections. For CRF-stimulated cortisol, there was a weak 262 
effect for a faster decline (greater absolute value of decline slope) in women vs. men within 263 
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the IBS group (p=0.014). For ACTH-stimulated cortisol (Figure 3), there was a significant 264 
IBS*sex interaction effect on AUCi (p<0.001). Among men, AUCi was higher in IBS vs. HCs 265 
(p=0.009), but among women, AUCi was lower in IBS vs. HCs (p=0.006).  Likewise, within IBS, 266 
AUCi was higher in men vs. women (p=0.012), but the opposite was true within HCs (see 267 
above). There was also a significant IBS*sex interaction effect on rise slope (p=0.008), which 268 
was greater in IBS men vs. HC men (p=0.006) and in HC women vs. HC men (p=0.006). Using 269 
mixed models, there was a significant IBS*sex*time interaction for ACTH-stimulated cortisol 270 
(p=0.0002). The differences between men and women were in the opposite direction in IBS 271 
vs. HCs. Although the interactions were not significant for CRF-stimulated ACTH or cortisol 272 
(p=0.35, p=0.11), visualization of the plotted responses (Figures 1-3) showed similarly 273 
divergent effects of IBS in men and women.  274 
3.5 GR mRNA 275 
There was a significant effect of IBS on GRα mRNA (Figure 4, IBS<HC, p=0.013) but not 276 
GRβ. This was mainly due to lower GRα mRNA in men (IBS vs. HC, p=0.007). There was no 277 
effect of sex on GRα or GRβ. Increased severity of overall IBS symptoms was associated with 278 
lower GRα mRNA (β=-5.1, p=0.046). There was a weak effect for a similar association with 279 
abdominal pain severity (β=-4.8, p=0.051, Figure 5A). Within the 48 participants comprising 280 
the hormone challenge/GR mRNA overlap subset, GRα mRNA was positively correlated with 281 
cortisol at 3:00pm (CRF-stimulation test; r=0.358, p=0.021), and negatively correlated with 282 
CRF-stimulated ACTH AUCi (r=-0.517, p=0.001, Figure 5B). 283 
3.6 Early Adverse Life Events 284 
There were no effects of EAL or interaction effects with IBS on baseline, AUCi, rise 285 
slope or decline slope (p>0.1 for all). However, a higher Total ETI-SR score (i.e., total number 286 
of EAL items) was associated with increased CRF-stimulated cortisol AUCi (p=0.019) and rise 287 
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slope (p=0.007) and a slower decline in ACTH-stimulated cortisol (p=0.014). Using mixed 288 
models, a history of EAL (EAL*time interaction) and EAL*IBS*time had non-significant effects 289 
on all hormone tests (for CRF-stimulated ACTH and cortisol and ACTH-stimulated cortisol, 290 
respectively, EAL*time: p=0.095, p=0.30, p=0.12; EAL*IBS*time: p=0.22, p=0.12, p=0.82). 291 
There was no effect of EAL on GRα or GRβ. 292 
3.7 Bowel Habit 293 
The hormone resonses over time by bowel habit are shown in Appendix B.5 294 
(Supplementary Material). There was a Group*time (IBS-C, IBS-D, IBS-M, HC) effect for CRF-295 
stimulated ACTH (p=0.008) and ACTH-stimulated cortisol (p=0.005). In both cases, the 296 
primary difference was due to the IBS-C group, which had a slower rise and decline than the 297 
other three groups. The IBS-C group also had a higher baseline AM cortisol (ACTH stimulation 298 
test; p<0.001) compared to each of the other groups. 299 
4. Discussion 300 
The main findings of this study include: 1) similar ACTH and cortisol response to CRF in 301 
IBS vs HCs; 2) sex-specific disease-related changes in the cortisol response to ACTH with an 302 
increased reponse in men with IBS vs HC men and a blunted response in women with IBS vs HC 303 
women; 3) disease-specific sex-related changes in the cortisol response to ACTH with an 304 
increased response in women vs men among HCs and the opposite among IBS; 3) reduced 305 
expression of PBMC GRα mRNA in IBS vs. HC (primarily in men); 4) an inverse relationship 306 
between GRα mRNA in PBMCs and the pituitary response to CRF as well as symptom severity 307 
in IBS; and 5) a positive association between the number of EAL events and the cortisol 308 
response to CRF. We also found an effect of bowel habit subtupe on HPA axis response with 309 
an increased baseline and blunted response in CRF-stimulated ACTH and ACTH-stimulated 310 
cortisol. To our knowledge, this is the largest and most comprehensive study characterizing 311 
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the HPA axis in IBS patients, taking the contributions of sex and history of EALs into account.  312 
4.1 HPA axis response in IBS vs HCs 313 
Our findings do not support the hypothesis that IBS is associated with an augmented 314 
cortisol or ACTH response to CRF stimulation. In two of three previous CRF stimulation studies 315 
in IBS, HPA axis response was greater in IBS vs. HCs.(Dinan et al., 2006; Fukudo et al., 1998) 316 
Differences may be related to the use of human and not ovine CRF in one study,(Bradford et 317 
al., 2012; McGowan et al., 2009b; Videlock et al., 2009) and differences in the sample of IBS 318 
patients (IBS-M and IBS-D were the majority in both).(Fukudo et al., 1998) In contrast, the 319 
third study(Dinan et al., 2006; Fukudo et al., 1998) showed a blunted HPA response in IBS.  In 320 
this latter study, there was a higher prevalence of psychiatric comorbidity, and IBS patients 321 
(bowel habit not specified) had a blunted waking cortisol, which contrasts with findings of 322 
most studies.(Bohmelt et al., 2005)  323 
4.2 HPA axis response in men vs women 324 
We found that among HCs, HPA response was increased in women vs. men. This is in 325 
agreement with other studies showing an increased HPA response to CRF in women following 326 
stress,(Eriksson et al., 2008; Patacchioli et al., 2014; Suarez-Hitz et al., 2012) or 327 
dexamethasone.(Young and Altemus, 2004) Sex differences may be due to opposing effects of 328 
ovarian hormones and androgens on CRF expression and GR expression (ovarian hormones 329 
increase CRF and decrease GR). Human studies in healthy individuals have demonstrated 330 
increased cortisol response in post-pubertal females compared to males.(Kunugi et al., 2005) 331 
Animal studies have also found decreased expression and glucocorticoid binding of GRs in the 332 
hypothalamus and pituitary in females and sex-differences in CRF1 receptor signaling and 333 
trafficking.(Panagiotakopoulos and Neigh, 2014)  334 
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4.3 Divergent IBS-related changes in men vs. women 335 
At the adrenal level, we found divergent IBS-related changes in men vs. women. While 336 
the cortisol response to ACTH stimulation was greater in IBS vs. HCs within men, it was 337 
blunted within women. Although not statistically significant, the divergent HPA responses to 338 
between IBS and HCs within men and women were similar with CRF stimulation. Although the 339 
response to a psychological stressor is often increased in men vs. women,(Bangasser and 340 
Valentino, 2014) there is good evidence that HPA response varies by type of challenge. Even 341 
among similar stressors, cortisol responses were greater in men vs. women to achievement 342 
challenges, but were greater in women to social rejection challenges.(Kudielka and 343 
Kirschbaum, 2005) Women have also been shown to have increased brain activation to 344 
negative emotions in several regions, including the amygdala.(Stroud et al., 2002) 345 
The difference between a hormonal vs. a contextual stressor may be particularly 346 
relevant in IBS as IBS has been associated with changes in several components of the 347 
integrated response to a stressor that may result in changes in the HPA axis response. 348 
Increased brain activity in emotional arousal circuits that include the amygdala and decreased 349 
activity of pain modulatory circuits that include the prefrontal cortex have been associated 350 
with IBS.(Stevens and Hamann, 2012) Both increased activity in the amygdala and decreased 351 
activity in the prefrontal cortex could result in an increased HPA axis response.(Mayer and 352 
Tillisch, 2011) In addition, IBS patients have increased cardiosympathetic tone, which may 353 
also result in an increased HPA response, and this was seen primarily in men.(Smith and Vale, 354 
2006) 355 
4.3 PBMC GR mRNA expression is reduced in IBS and is negatively correlated with the 356 
ACTH response to CRF 357 
IBS was associated with decreased GRα mRNA expression. This difference was mainly 358 
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due to a difference among men. GR is a transcription factor of the nuclear receptor family 359 
(Official gene symbol: NR3C1). When bound to a ligand, it translocates to the nucleus and 360 
binds to glucocorticoid response elements to regulate downstream expression of genes 361 
primarily involved in the inflammatory response. The α isoform is the active isoform and the β 362 
isoform does not bind ligand and has a dominant negative effect on the transcriptional 363 
activity of GRα.(Tillisch et al., 2005) Expression of the inactive GRβ, which was not different 364 
in IBS vs. HCs, has been associated with glucocorticoid resistance in several diseases including 365 
ulcerative colitis (there was no difference in GRα mRNA in this study).(Lewis-Tuffin and 366 
Cidlowski, 2006) While expression of the inactive GRβ plays an important role in inflammatory 367 
disorders, expression of GRα has been associated with stress-related and psychiatric 368 
disorders. There are no other published studies of GR mRNA in IBS, but lower PBMC GRα mRNA 369 
was also found in association with fibromyalgia,(Honda et al., 2000) which has shared 370 
pathophysiology with IBS, and in post-traumatic stress disorder.(Macedo et al., 2008) Limited 371 
evidence for a link between peripheral and central GR expression exists.(Gola et al., 2014) In 372 
a study in rats, chronic treatment with corticosterone decreased GR in both lymphocytes and 373 
in the hippocampus.(Hepgul et al., 2013) In humans, PBMC GR density was decreased in 374 
patients with depression pre-treatment and increased following successful treatment with 375 
antidepressants, (Lowy, 1991) and increased suppression of cortisol following dexamethasone 376 
was associated with lower methylation of the GR promoter in PBMCs.(Calfa et al., 2003)  377 
Our findings of concordant group differences in HPA response and GRα expression 378 
among men with IBS vs. HC men (increased HPA axis response and decreased GR mRNA 379 
expression) as well as a negative correlation between GRα expression and CRF stimulated 380 
ACTH response provides additional evidence that PBMC GRα expression may be a peripheral 381 
marker of central HPA activity, and could support impaired negative feedback as a 382 
mechanism of HPA axis dysregulation in men with IBS. Alternatively, changes in peripheral 383 
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GRα mRNA expression may occur as a result of increased HPA activation rather than reflecting 384 
a causative mechanism (alterations in central gene expression). It should be noted that mRNA 385 
expression does not necessarily reflect receptor function; there are post-transcriptional and 386 
post-translational regulatory mechanisms that can regulate GR signaling, and in one study, 387 
trauma-associated changes in PBMC GR number as assessed by dexamethasone binding 388 
capacity, were not reflected in mRNA expression.(Yehuda et al., 2015)  389 
In summary, our results support the hypothesis that PBMC GR mRNA expression is a 390 
peripheral marker of central HPA axis activity. While the findings are consistent with 391 
impaired negative feedback, they are inconclusive for the reasons described above. Other 392 
existing, albeit limited, data have not supported impaired negative feedback including normal 393 
dexamethasone suppression,(van Zuiden et al., 2011)  and in a pilot study (n=27), we 394 
evaluated the response to dexamethasone-CRF and found it to be similar in IBS vs. 395 
HCs.(Bohmelt et al., 2005; Dinan et al., 2006)  As described in section 4.3, the fact that an 396 
augmented HPA axis reponse has been seen in IBS in reponse to psychological stressors in the 397 
context of our findings of similar reponses at the pituitary level in HCs and IBS also supports 398 
increased neural regulation or “CRF-hyperdrive” in IBS rather than impaired negative 399 
feedback. Interestingly, Ehlert et. al. found that when they divided their sample by level of 400 
awakening cortisol, the group with high cortisol had higher levels of depression symptoms and 401 
lower GI symptom scores than the other groups, suggesting different effects of psychological 402 
symptoms and IBS on the HPA axis.(Videlock et al., 2015) 403 
4.4 Influence of early adverse life events 404 
We did not find that the presence or absence of EALs affected the HPA response to 405 
hormone challenge; however, among all participants, a higher number of EAL events was 406 
associated with an increased CRF-stimulated cortisol response. We previously demonstrated 407 
an increased salivary cortisol response to flexible sigmoidoscopy associated with EAL, 408 
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predominantly in men.(Ehlert et al., 2005) The smaller effect of EAL on hormone challenge 409 
vs. a visceral stressor is likely related to the differences in the types of provocation; flexible 410 
sigmoidoscopy is a physical and likely psychological stressor.  411 
4.5 Bowel habit subtype and symptoms 412 
HPA response and baseline cortisol was affected by bowel habit subtype.  The most 413 
prominent difference was a higher baseline and blunted response in CRF-stimulated ACTH and 414 
ACTH-stimulated cortisol in IBS-C. Other studies have also shown differences in measures of 415 
both the HPA axis and the autonomic nervous system by bowel habit subtype.(Videlock et al., 416 
2009) For example, Burr et al found significantly higher cortisol levels in women with IBS-C 417 
during sleep compared to both IBS-D and HCs.(Suarez-Hitz et al., 2012) 418 
We did not find an association between HPA response and overall IBS symptom or 419 
abdominal pain severity. Interestingly, studies have not consistently shown differences in the 420 
HPA response between IBS patients and HCs to perturbations of the gut, which the brain may 421 
perceive as stressful events. This includes stimulation by a meal,(Burr et al., 2009) flexible 422 
sigmoidoscopy,(Elsenbruch et al., 2004) and rectal distention.(Chang et al., 2009) However, 423 
there is one study in which increased HPA suppression (lower post dexamethasone cortisol) 424 
was associated with increased IBS-like symptoms in healthy controls.(Walter et al., 2006) In 425 
addition, higher doses of CRF have been shown to affect motility and symptoms in IBS 426 
patients(Karling et al., 2007) and HCs.(Fukudo et al., 1998) We did find an association 427 
between increased symptom severity and decreased GR mRNA expression. If decreased GR 428 
expression is a response to HPA axis activation as hypothesized (discussed below), this would 429 
support an association between symptom severity and activation of the HPA axis. 430 
4.4 Limitations 431 
This study has limitations. Differences in cortisol may have been obscured by our 432 
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decision to measure total plasma cortisol and not salivary or serum free cortisol. In addition, 433 
not all women were in the follicular phase of the menstrual cycle. This was unlikely to have 434 
impacted the results as we did not find differences associated with menstrual cycle. 435 
Additionally, women in the luteal phase would likely introduce a conservative bias, if any, as 436 
luteal phase women have salivary cortisol (but not total plasma cortisol) responses to 437 
stressors that are similar to men.(Pritchard et al., 2015)  438 
5. Conclusions and clinical implications 439 
In conclusion, we provide further evidence that IBS is associated with a dysregulated 440 
HPA response to hormone challenge, with divergent IBS-related changes in men vs. women. 441 
IBS men vs. HC men had an enhanced HPA response and this was associated with a concordant 442 
reduction in GRα mRNA expression in PBMCs. Hormone challenge tests the endocrine 443 
regulation of the HPA response to a weight-based dose of CRF, whereas the HPA response to a 444 
stressor depends on the neural regulation which is affected by the salience of the stressor and 445 
the “wiring” of brain circuits with inputs into the hypothalamus. An increased HPA response 446 
to stressors(Kudielka and Kirschbaum, 2005) but not to hormone challenge in IBS women, in 447 
combination with both increased emotional response(Kennedy et al., 2014) and increased 448 
connectivity of emotional-arousal circuits(Chang et al., 2006) in response to visceral 449 
distension, supports higher order cognitive and emotional processes as key factors in the 450 
relationship of stress and symptoms in women with IBS. The ability to better understand 451 
endophenotypes within IBS that may have divergent dysregulation of the HPA axis will be 452 
important in developing treatments targeted at different subgroups.  453 
  454 
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Figure Legends 598 
Figure 1. The ACTH response to CRF is shown by subgroup to highlight the following 599 
comparisons: A) men with IBS vs HC men; B) women with IBS vs. HC women; C) HC men vs. HC 600 
women; and D) women with IBS vs. men with IBS.  IBS*sex interaction for AUCi was not 601 
statistically significant. Baseline ACTH was increased in men vs women (p < 0.001, for women 602 
vs. men overall: C+D) 603 
CRF, corticotropin-releasing factor; ACTH, adrenocorticotrophic hormone; pg, picograms; mL, 604 
milliliter; HC, healthy control, IBS, irritable bowel syndrome 605 
606 
Figure 2. The cortisol response to CRF is shown by subgroup to highlight the following 607 
comparisons: A) men with IBS vs HC men; B) women with IBS vs. HC women; C) HC men vs. HC 608 
women; and D) women with IBS vs. men with IBS.  IBS*sex interaction for AUCi was not 609 
statistically significant. Within the IBS group (D), decline was faster in men vs. women 610 
(p=0.014) 611 
CRF, corticotropin-releasing factor; mL, milliliter; HC, healthy control, IBS, irritable bowel 612 
syndrome; M, men; W, women; μg, micrograms; dL deciliter 613 
614 
Figure 3. The cortisol response to ACTH is shown by subgroup to highlight the following 615 
comparisons: A) men with IBS vs HC men; B) women with IBS vs. HC women; C) HC men vs. HC 616 
women; and D) women with IBS vs. men with IBS. IBS*sex for AUCi: p<0.001. Among men IBS 617 
had greater AUCi (A, p=0.009), but AUCi was higher in HCs among women (B, p=0.006). IBS*sex 618 
interaction was also significant for rise slope (p=0.008) with both IBS men(A) and HC 619 
women(C) > HC men (p=0.006 for both). A) .  Decline was also faster in women vs men (C, 620 
p=0.012). 621 
ACTH, adrenocorticotrophic hormone;  mL, milliliter; HC, healthy control, IBS, irritable bowel 622 
syndrome; M, men; W, women; μg, micrograms; dL deciliter 623 
624 
Figure 4. Glucocorticoid receptor α mRNA expression was lower in IBS vs HCs overall 625 
(p=0.013); however, this difference was mainly accounted for by a difference among men 626 
(p=0.007) 627 
HC, healthy control; IBS, irritable bowel syndrome; GR, glucocorticoid receptor 628 
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629 
Figure 5. Glucocorticoid receptor α mRNA is associated with baseline cortisol (A) and the 630 
ACTH response to CRF (AUCi). N=47 (GR mRNA/hormone challenge overlap group). The value 631 
for r is the partial correlation controlling for time in days between collection (mean(SD): 27.0 632 
(31.8)) of each measure. Baseline is at 3:00pm on the day of the CRF-stimulation test. 633 
GR, glucocorticoid receptor; CRF, corticotrophin releasing factor; ACTH, adrenocorticotrophic 634 
hormone; AUCi, area under the curve with respect to increase; pg, picrograms; dL deciliter; 635 
min, minute 636 
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